HC Wainwright Issues Pessimistic Outlook for SRTS Earnings

Sensus Healthcare, Inc. (NASDAQ:SRTS) – HC Wainwright dropped their Q1 2025 earnings per share estimates for shares of Sensus Healthcare in a note issued to investors on Monday, February 10th. HC Wainwright analyst Y. Chen now forecasts that the company will earn $0.11 per share for the quarter, down from their previous estimate of $0.14. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.71 per share. HC Wainwright also issued estimates for Sensus Healthcare’s Q3 2025 earnings at $0.10 EPS and Q4 2025 earnings at $0.16 EPS.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%.

Several other brokerages have also recently weighed in on SRTS. Lake Street Capital initiated coverage on shares of Sensus Healthcare in a research report on Friday, January 31st. They issued a “buy” rating and a $18.00 price target for the company. Maxim Group upped their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, November 15th.

Sensus Healthcare Trading Up 3.9 %

SRTS opened at $6.07 on Tuesday. The company has a market capitalization of $99.49 million, a price-to-earnings ratio of 15.18 and a beta of 1.24. The business’s fifty day simple moving average is $7.38 and its 200-day simple moving average is $6.89. Sensus Healthcare has a 12-month low of $2.91 and a 12-month high of $9.33.

Institutional Investors Weigh In On Sensus Healthcare

A number of large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP increased its holdings in shares of Sensus Healthcare by 128.0% in the second quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock valued at $888,000 after purchasing an additional 93,511 shares during the period. Geode Capital Management LLC raised its holdings in shares of Sensus Healthcare by 8.5% during the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock worth $849,000 after purchasing an additional 11,525 shares during the last quarter. Ritholtz Wealth Management lifted its position in Sensus Healthcare by 65.3% during the fourth quarter. Ritholtz Wealth Management now owns 51,261 shares of the company’s stock valued at $355,000 after purchasing an additional 20,256 shares during the period. XTX Topco Ltd boosted its holdings in Sensus Healthcare by 76.0% in the third quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after purchasing an additional 13,619 shares during the last quarter. Finally, Sigma Planning Corp acquired a new stake in Sensus Healthcare during the 4th quarter worth about $215,000. 25.30% of the stock is owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.